Vamifeport, a clinical stage oral ferroportin inhibitor, alleviates murine lupus nephritis: A pilot study
Clinical Immunology · 2026-06 · 285 · 110699
DOI: 10.1016/j.clim.2026.110699 ↗Kurz gefasst
Fachartikel in der Zeitschrift Clinical Immunology, 2026-06. Verfasst von Divya Katikaneni und 7 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medicine, and Molecular Genetics and Microbiology, University of Florida, USA. Hauptthemen laut MEDLINE: Lupus Nephritis, Cation Transport Proteins. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 73 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NIDDK NIH HHS, Vifor Pharma Management AG, National Institutes of Health.
Abstract (Originalsprache)
Even after immunosuppression, the rate of complete remission for proliferative lupus nephritis (LN) remains around 50%, highlighting the need for identifying novel therapeutic targets. Iron exacerbates LN, and treatment with hepcidin, the primary regulator of systemic iron metabolism, ameliorates LN. This identifies ferroportin, the only known hepcidin receptor, as a target to alleviate LN. Vamifeport is a safe oral ferroportin inhibitor with promising pharmacodynamic effect, currently in clinical development for diseases with dysregulated iron metabolism. We demonstrate that oral vamifeport administration attenuates renal pathology in MRL/lpr mice, independently of circulating autoantibodies and glomerular immune complex deposits. We identified that vamifeport reduces ferroportin expression on monocytes. LN serum-induced inflammation is attenuated only in long-term vamifeport treated monocyte-derived macrophages (MDM), but not in renal proximal tubular epithelial cells (ferroportin-expressing cells in the kidney). Collectively, our study suggests that vamifeport has a high potential to be further developed clinically as an adjunct therapeutic to treat LN.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Medicine, and Molecular Genetics and Microbiology, University of Florida, USA.
- Department of Microbiology, Immunology, and Molecular Genetics, UT Health, San Antonio, TX, USA.
- CSL Research, Research Zurich, Switzerland.
- Department of Medicine, and Molecular Genetics and Microbiology, University of Florida, USA. Electronic address: yogesh.scindia@medicine.ufl.edu.
Förderung
- NIDDK NIH HHS
- Vifor Pharma Management AG
- National Institutes of Health
- National Institute of Diabetes and Digestive and Kidney Diseases
Zitieren
APA
Katikaneni, D., Arekar, T., Al-Hraki, L., Garcia, G., Reedy, N., Morel, L., Manolova, V., & Scindia, Y. (2026). Vamifeport, a clinical stage oral ferroportin inhibitor, alleviates murine lupus nephritis: A pilot study. Clinical Immunology, 285, 110699. https://doi.org/10.1016/j.clim.2026.110699
Vancouver
Katikaneni D, Arekar T, Al-Hraki L, Garcia G, Reedy N, Morel L, et al. Vamifeport, a clinical stage oral ferroportin inhibitor, alleviates murine lupus nephritis: A pilot study. Clinical Immunology. 2026;285:110699. doi:10.1016/j.clim.2026.110699
BibTeX
@article{Katikaneni2026,
author = {Katikaneni, Divya and Arekar, Tanmay and Al-Hraki, Leena and Garcia, Gabriella and Reedy, Norah and Morel, Laurence and Manolova, Vania and Scindia, Yogesh},
title = {Vamifeport, a clinical stage oral ferroportin inhibitor, alleviates murine lupus nephritis: A pilot study},
journal = {Clinical Immunology},
year = {2026},
volume = {285},
pages = {110699},
doi = {10.1016/j.clim.2026.110699}
}
EUVIMED